The UK Regulator have issued an allergy warning on Pfizer COVID-19 Vaccine, and have advised people having a history of “significant” allergic reactions to not get the Pfizer-BioNTech vaccine.
The precautionary advice has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) to the National Health Service (NHS) after two health care staff members experienced allergic reactions.
NHS England confirmed that both staff members have a major history of allergic reactions to the extent that they need to carry an adrenaline auto-injector with them.
ALSO READ| 90-year-old British Woman Becomes The First Person In The World To Receive Pfizer Covid-19 Vaccine
Shortly after the two staff members were administered with the first dose of Pfizer’s vaccine, they developed symptoms of “anaphylactoid reaction”. They are currently recovering after receiving appropriate treatment, according to reports of British media.
The MHRA has advised that people with such “significant” allergic reactions to medicines, food or vaccines should not get the vaccine jab. Dr June Raine, chief executive of the MHRA, confirmed to a parliamentary committee on Wednesday, that the cases of allergic reactions didn’t feature in the extensive clinical trials.
“We know from the very extensive clinical trials that this wasn’t a feature. But if we need to strengthen our advice, now that we’ve had this experience in the vulnerable populations – the groups have been selected as a priority – we get that advice to the field immediately,” said Dr Raine.
On Tuesday, Britain rolled out the Covid-19 vaccine developed by Pfizer and BioNTech, and became the first Western nation to start vaccinating its general population.
Margaret Keenan, a 90-year-old grandmother from Britain, became the first person in the world to receive the Pfizer’s Covid-19 vaccine outside of a trial.
ALSO READ| COVID-19 Vaccine To Be Available By The End Of This Year? Oxford On Verge Of One, Says UK PM Boris Johnson
The Data Monitoring Committee for the study of phase 3 trial of Pfizer’s vaccine has not reported any serious safety concerns related to the vaccine. It reported some cases of fatigue and headache after the volunteers received the second dose of the vaccine.
“The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2,” Pfizer had said in a statement.